Monocard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Monocard

What is Monocard?

Monocard is a medication containing the active ingredient isosorbide mononitrate. It belongs to a class of drugs known as organic nitrates, which are primarily used in the management of certain heart-related conditions.

Mechanism of Action

Isosorbide mononitrate works by relaxing the smooth muscles within the walls of blood vessels. This relaxation leads to the widening of the vessels, a process called vasodilation. By dilating the veins and arteries, the medication reduces the workload on the heart and improves blood flow. This mechanism helps to ensure that the heart muscle receives an adequate supply of oxygenated blood.

Primary Use

Monocard is used for the long-term prevention of angina pectoris. Angina is characterized by chest pain or discomfort that occurs when the heart muscle does not receive enough oxygen-rich blood.

It is important to note that Monocard is designed for chronic management and prophylaxis. Due to the time it takes for the medication to be absorbed and become active in the body, it is not intended for the immediate relief of an acute, sudden attack of angina.

Regulatory References

  1. Isosorbide - StatPearls - NCBI Bookshelf
  2. NIH DailyMed

What side effects are possible with Monocard?

Possible Side Effects and Safety Information

The safety profile of Monocard (Isosorbide Mononitrate) is characterized by adverse reactions predominantly related to its mechanism as a vasodilator, as documented in regulatory prescribing information.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on their observed occurrence:

Classification Examples of Adverse Reactions
Very Common (ge 1/10) Headache
Common (ge 1/100 to < 1/10) Dizziness, Hypotension (orthostatic), Tachycardia, Nausea
Uncommon (ge 1/1,000 to < 1/100) Facial flushing, Vomiting, Circulatory collapse
Very Rare (< 1/10,000) Exfoliative dermatitis

The most frequent effect, headache, is commonly observed at the start of therapy and typically diminishes after one to three weeks of continuous use. Hypotension and dizziness are also often noted during treatment initiation and may lessen over time.

Serious Safety Constraints

The regulatory profile identifies certain critical situations and patient groups. Severe Hypotension and Circulatory Collapse are documented as serious adverse reactions. A major safety restriction is the absolute contraindication of Monocard with specific drugs, such as phosphodiesterase inhibitors (e.g., sildenafil), due to the high risk of life-threatening severe hypotension.

Population-Specific Notes

The safety profile includes considerations for certain populations: Older adults may have an increased susceptibility to orthostatic hypotension. The safety and effectiveness of Monocard in pediatric patients and during pregnancy or lactation have not been established in regulatory documents.

Overdose and Emergency Response

Overdose with Monocard (Isosorbide Mononitrate) is primarily characterized by clinical manifestations resulting from excessive vasodilation, which may lead to severe hemodynamic instability. Officially documented presentations include a prompt fall in blood pressure (hypotension), syncope (fainting), and tachycardia (fast heart rate). Central nervous system effects often accompany these signs, such as a persistent throbbing headache, vertigo, confusion, and visual disturbances. Gastrointestinal symptoms like nausea, vomiting, and even bloody diarrhea have been documented in regulatory records.

Severe or life-threatening outcomes can include circulatory failure, convulsions, or the development of Methaemoglobinaemia, a serious condition that may present with cyanosis (bluish coloration of the skin).

In all cases of suspected overdose, particularly when severe symptoms such as syncope or signs of circulatory collapse occur, immediate medical attention must be sought. Official regulatory guidance for management focuses on symptomatic and supportive treatment, including the correction of hypotension through measures to expand central fluid volume. The use of agents such as epinephrine to treat hypotension is documented as not recommended. The specific complication of Methaemoglobinaemia is addressed with the documented use of Methylene blue. Specific populations, notably patients with renal failure or congestive heart failure, require cautious management due to the potential hazards of fluid expansion therapy.

Therapeutic Uses of Monocard

Main Uses and Therapeutic Intent

Monocard contains isosorbide mononitrate, an active substance belonging to a group of medicines known as organic nitrates. It is primarily used for the long-term management and prevention of angina pectoris, a condition characterized by chest pain or discomfort that occurs when a part of the heart muscle does not receive enough oxygen-rich blood.

By acting as a vasodilator, the medication helps to relax and widen the blood vessels. This process reduces the workload on the heart and improves blood flow to the cardiac muscle, thereby preventing the onset of chest pain episodes.

Chronic Stable Angina

The medication is indicated for the prophylactic treatment of chronic stable angina. In this context, it is used to reduce the frequency and severity of angina attacks in patients who experience predictable symptoms during physical exertion or emotional stress. It is important to note that this medication is intended for maintenance therapy and is not suitable for the immediate relief of an acute, sudden attack of angina.

Benefits in Cardiac Management

The primary benefits of treatment involve the systematic improvement of cardiac efficiency through the following mechanisms:

  • Reduction in Cardiac Preload: By dilating the venous system, the medication decreases the volume of blood returning to the heart. This lowers the pressure within the heart chambers and reduces the amount of work the heart must perform.
  • Reduction in Cardiac Afterload: To a lesser extent, the medication also relaxes the arterial walls, which decreases the resistance the heart must pump against to circulate blood throughout the body.
  • Improved Oxygen Supply: Through the dilation of coronary arteries, the medication can enhance the delivery of oxygen to myocardial tissues, helping to balance the heart's oxygen demand with its supply.

Long-term Prophylaxis

For individuals with coronary artery disease, the regular use of this medication aims to increase exercise tolerance and improve the overall quality of daily life by minimizing the physical limitations imposed by chronic chest pain. It is often used as part of a broader therapeutic strategy to manage ischemic heart disease over the long term.

Eligibility and Restrictions for Use

Who Can and Cannot Use Monocard? (Isosorbide Mononitrate)

The official eligibility for Monocard is strictly defined by regulatory documents, distinguishing between permitted use, conditions requiring caution, and absolute prohibitions (contraindications).

Contraindications (Must Not Use)

Monocard is contraindicated for patients with a known hypersensitivity to any nitrate, including isosorbide mononitrate. Absolute prohibition applies to patients currently receiving Phosphodiesterase type-5 (PDE-5) inhibitors (e.g., sildenafil) or riociguat.

Contraindications also include conditions like marked hypotension (Systolic BP le 90 mmHg), acute circulatory failure or shock, and certain cardiac conditions such as cardiogenic shock or constrictive pericarditis.

Population and Condition Restrictions

Population Group Regulatory Status Status Detail
Adults Permitted Use Approved population for long-term treatment.
Pediatric Patients Not Recommended Safety and efficacy have not been established.
Older Adults Caution Required Use with caution due to increased risk of hypotension.
Severe Hepatic Impairment Restricted Use Requires special care or use with caution.
Pregnancy/Lactation Conditional Use Use only if potential benefit justifies the risk to the fetus; caution during lactation.

Use also requires caution in patients with hypovolaemia, certain types of cerebrovascular insufficiency, or marked anaemia, as officially stated in labeling.

What should I know about interactions with other medicines?

️ Interaction Scope and Restrictions

The regulatory profile for Monocard is primarily defined by interactions that cause a pronounced pharmacodynamic reinforcement of its vasodilating action, leading to severe hypotension. This mandates strict restrictions on co-administration with other substances that lower blood pressure.

Category Description
Medicinal Product Categories Phosphodiesterase Type 5 (PDE5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Vasodilators, Anti-hypertensive Medications, Alcohol.
Interaction-Related Restrictions Absolute prohibition on co-administration with all PDE5 inhibitors (e.g., Sildenafil, Tadalafil) and the sGC stimulator Riociguat.

Interaction Classifications

The most critical interaction classification is Contraindicated, as strictly defined in official prescribing information across major government health authorities (e.g., FDA, EMA).

Official Interaction Statements:

  • Co-administration with PDE5 inhibitors and sGC stimulators is forbidden due to the risk of severe, life-threatening hypotension and cardiovascular collapse.
  • Concurrent use with Alcohol (Ethanol) may result in excessive blood pressure lowering and increased risk of postural effects.
  • The use of other anti-hypertensive medications or vasodilators may result in reinforced blood pressure reduction.
  • In emergency situations, a time separation window (e.g., a minimum of 24 hours) is typically mandated after the last dose of Sildenafil before a nitrate can be administered.
  • Food intake does not alter the total drug exposure for the extended-release tablet but may decrease the rate of absorption.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure primarily through additive hypotensive effects, which establishes absolute prohibitions against co-administration with other potent vasodilators.

Mechanism of Action

Monocard (Isosorbide Mononitrate) is an organic nitrate prodrug that acts by modulating cellular signaling within vascular smooth muscle. The mechanism modifies cellular dynamics in blood vessel walls, resulting in changes to systemic blood flow and pressure.

Activation of the Nitric Oxide-cGMP Pathway

The drug's action begins with the bioactivation of Isosorbide Mononitrate within the vascular smooth muscle cells, which releases Nitric Oxide (NO). This NO acts as an endogenous signal, directly stimulating the enzyme soluble Guanylate Cyclase (sGC) and initiating a molecular cascade that increases the concentration of the secondary messenger cGMP.

Vascular Smooth Muscle Relaxation and Vasodilation

The elevated cGMP concentration triggers relaxation by causing the de-phosphorylation of myosin light chains and a reduction in the intracellular calcium ions ( Ca^2+) required for muscle contraction. This process causes vasodilation (widening of the blood vessels) across the systemic circulation, with a functionally dominant effect on the venous capacitance vessels.

Modulating Cardiac Hemodynamics and Preload

The dominant physiological consequence is the increase in venous pooling in the periphery, which reduces the volume and pressure of blood returning to the heart. This action reduces the cardiac preload and, by decreasing the ventricular wall tension, results in a lower myocardial oxygen demand.

Dosage and Administration Information

The administration of Monocard (Isosorbide Mononitrate) is governed by specific guidelines to ensure a structured, non-continuous dosing pattern. The medication is for oral use only and is supplied as either an Immediate-Release (IR) or Extended-Release (ER) tablet.


Administration Schedule and Dosing

Administration Component Official Guidelines
Standard Adult Dosing IR: 20 mg taken twice daily, often starting with a lower dose of 5 mg to 10 mg. ER: 30 mg to 60 mg taken once daily, with the maximum dose reaching 240 mg once daily.
Timing and Frequency IR: Doses must be separated by exactly seven hours to create a mandatory daily nitrate-free interval. ER: The tablet is taken once daily in the morning.
Preparation & Intake The ER tablet must be swallowed whole with fluid and is never to be chewed, crushed, or split. The IR tablet should be taken on an empty stomach.

Procedural and Population-Specific Rules

When initiating treatment, older adults should be started at the lower end of the established dose range. If a dose is missed, it must be skipped if the next scheduled dose is approaching, in order to preserve the dosing interval; do not take a double dose. The medication is designated only for long-term prophylaxis and is not intended for use during an acute event. Furthermore, treatment should never be stopped suddenly; the dosage and frequency must be tapered gradually before discontinuation.

Recent Clinical Evidence

Research Evidence: Overview of Monocard Studies

This section provides a factual summary of the clinical research supporting Monocard (Isosorbide Mononitrate), focusing strictly on the types of studies conducted, the populations included, and the key questions researchers sought to answer, based on official regulatory and scientific documents.


Evidence for Stable Angina Pectoris (Chest Pain Prophylaxis)

Studies for Monocard primarily involve Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were used in research exploring how symptoms change over time in adults with stable angina pectoris. Researchers sought to evaluate the medicine by monitoring functional outcomes such as exercise tolerance time and patient-reported outcomes describing perceived discomfort, like the frequency of angina attacks. Changes in measured exercise capacity were reported in the group receiving Monocard compared to those on placebo.

Research consistently notes the challenge of pharmacological tolerance, where the consistency of the measured effect was observed to diminish over time in some study designs. Furthermore, the available evidence largely focuses on short-term symptom changes, meaning long-term effects on major cardiovascular events are not as fully established compared to trials focusing on these hard outcomes.


Evidence for General Coronary Artery Disease Management

Evidence for Monocard in the context of Coronary Artery Disease (CAD) management has been evaluated through Observational Cohort Studies and real-world analyses. The outcomes assessed included parameters that monitor physiological strain placed on the heart, such as the pressure of blood returning to the heart (cardiac preload). The research examined populations of adults diagnosed with stable CAD, including those with coexisting health conditions. Because much of the long-term data is observational, isolating the independent contribution of Monocard from other concurrent therapies can be challenging, and comparative evidence against certain foundational modern therapies is sometimes lacking.

Key Studies & References Isosorbide Mononitrate Extended-Release Tablet: DailyMed - NIH

Frequently Asked Questions (FAQ)

Common questions about Monocard (FAQ)

Q: How quickly does Monocard start working after I take it?

Official prescribing information indicates Monocard is designed for the long-term prevention of chest pain, a use known as prophylaxis. It is not intended to treat an acute or sudden angina attack. The extended-release form works by releasing the active ingredient slowly to provide a sustained effect over many hours.


Q: Is Monocard a type of blood pressure medicine?

Monocard is classified as a vasodilator, meaning it causes blood vessels to widen. Its main purpose is to reduce the workload on the heart by changing blood flow and pressure. While this action can cause a drop in blood pressure, the drug is primarily used for managing cardiac symptoms and not as a foundational treatment for high blood pressure (hypertension).


Q: Can Monocard be taken with common over-the-counter pain relievers?

Regulatory sources often note that pain relievers like Aspirin and Acetaminophen (Paracetamol) are commonly used to help with nitrate-induced headaches. However, official sources indicate caution may be required with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen. Any potential combination with Monocard should be discussed with a healthcare provider.


Q: Are there any foods or drinks I should avoid while taking Monocard?

Official drug labels specify that consumption of alcohol may lead to a more significant drop in blood pressure than expected. This can increase the risk of side effects such as light-headedness, dizziness, or fainting.


Q: Is Monocard known to cause weight gain or loss?

In reports compiled by regulatory authorities, weight gain is listed as an uncommon side effect, and weight loss is noted as rare. The most frequent side effects, such as headache and dizziness, are related to the medicine's primary action of widening blood vessels.


Q: Can Monocard affect my ability to drive or operate machinery?

Yes, official product information indicates that Monocard may impair the ability to safely drive or operate heavy machinery. This caution is based on common side effects such as dizziness, headache, and light-headedness, particularly when a person stands up quickly.


Q: Is Monocard safe for people who have kidney issues?

Regulatory documents suggest that impaired kidney function generally does not significantly change how the drug works in the body. However, caution may be required based on an individual's specific health profile. The regulatory information is used by a healthcare provider to determine the appropriateness of the drug for an individual patient.


Q: Can Monocard cause sleep problems or insomnia?

Yes, official regulatory documents list insomnia (trouble sleeping) as an uncommon adverse reaction associated with the medication.


Q: Is Monocard available as a generic version?

Yes, the active ingredient in Monocard, Isosorbide Mononitrate, has approved generic versions available from various manufacturers.


Q: Does Monocard have a black box warning?

No, the official FDA DailyMed label for Monocard (Isosorbide Mononitrate) does not contain a Black Box Warning. A Black Box Warning is the most severe safety advisory required by the Food and Drug Administration.


Q: What are the signs of a serious allergic reaction to Monocard?

Monocard is strictly contraindicated for anyone with a known hypersensitivity to nitrates. Signs of a serious allergic reaction can include swelling of the face, tongue, or throat, or difficulty breathing. The most serious adverse events related to the medication’s action include severe hypotension (very low blood pressure) and circulatory collapse.


Q: What kind of monitoring or tests are needed while on Monocard?

Routine blood tests or laboratory monitoring are not typically required for Monocard therapy. Monitoring usually focuses on clinical assessments, such as checking blood pressure and heart rate. Assessment of a patient’s symptoms, such as headaches, dizziness, and the frequency of chest pain, is also part of the clinical monitoring process.


Q: Does Monocard affect cholesterol levels?

While the drug is not known to directly change cholesterol levels, nitrates and nitrites may interfere with certain laboratory tests. Regulatory documents note that this interference can potentially cause falsely low readings when measuring cholesterol in the blood.


Q: Is Monocard a blood thinner?

No, Monocard is formally classified as an Organic Nitrate and a Vasodilator. It works by widening blood vessels, which reduces strain on the heart, and is not categorized as an anticoagulant or anti-platelet agent (a blood thinner).


Q: What happens if I accidentally take two doses of Monocard?

Official documents advise against taking a double dose. Signs of taking more than the prescribed amount (overdose) may include symptoms related to severe blood pressure lowering (hypotension). These signs can include flushing, intense headache, dizziness, fainting (syncope), and palpitations.


Q: Is there a risk of dependency or withdrawal when stopping Monocard?

Official guidelines state that Monocard should not be stopped suddenly, as this may lead to a worsening of chest pain symptoms. To manage the risk of physical dependence sometimes seen with nitrate exposure, the dosage and frequency are typically reduced gradually (tapered) by a healthcare provider before discontinuation.


Q: Does Monocard cause joint pain or muscle aches?

Joint pain (arthralgia) and muscle aches (myalgia) are both listed as uncommon adverse reactions in regulatory documents. This indicates that while possible, these side effects occur less frequently than the most common reactions like headache or dizziness.


Q: Is Monocard used to prevent future heart problems?

Monocard is officially used for the long-term prevention (prophylaxis) of symptoms like chest pain associated with coronary artery disease. However, regulatory sources mention that its effect on major cardiovascular events (like heart attacks or stroke) is not as fully established when compared to certain other foundational heart therapies.


Q: Can Monocard interact with herbal supplements like St. John's Wort?

Official sources generally do not contain specific data on interactions with most herbal supplements. Due to this lack of conclusive information, regulatory information suggests there is insufficient data to confirm that herbal remedies do not interact with Monocard.


Q: Are there any lifestyle changes recommended when starting Monocard?

Official sources note that support for cardiovascular health often involves certain practices, such as avoiding smoking and limiting intense physical activity that may provoke chest pain. Avoiding alcohol is also noted in regulatory labels due to a known interaction risk.


Q: Does Monocard affect fertility in men or women?

According to the official product information, studies conducted in animals found no adverse effects on reproductive capability or fertility. There is currently no controlled clinical data available specifically regarding the effect of Monocard on human fertility.


Q: What happens if I forget to store Monocard properly (e.g., leave it in a hot car)?

Official guidelines indicate Monocard is stored within a specific controlled room temperature range. If the tablets have been exposed to temperature extremes, such as freezing or excessive heat (like inside a hot car), the medication's chemical stability or effectiveness may be reduced. If the product is exposed to temperatures outside of the specified range, official documents suggest the drug’s stability may be compromised, requiring its replacement.


Q: Is it normal to feel tired when first starting Monocard?

Tiredness, listed in regulatory documents as asthenia or malaise, is noted as an uncommon side effect. Additionally, common reactions like dizziness and low blood pressure (hypotension) can frequently contribute to a general feeling of weakness or being tired during the initial phase of treatment.


Q: Where can I find the official patient information leaflet (PIL) for Monocard?

The official Patient Information Leaflet (PIL) or Medication Guide is provided by the manufacturer and is often available on the websites of major government health authorities. Patients can typically find these official documents by searching for the active ingredient, Isosorbide Mononitrate, on sites like the FDA DailyMed or the EMA/MHRA.


Q: Have there been any recent safety alerts or recalls related to Monocard?

Information concerning any recent drug safety alerts or product recalls is communicated directly by government regulatory bodies. This information can be verified by checking the drug safety or recall databases maintained by agencies such as the FDA, EMA, or MHRA.

How should Monocard be stored and disposed of?

Storage Requirements

Monocard (Isosorbide Mononitrate) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C (59 F and 86 F) are permitted, but the product must not be exposed to freezing temperatures.

The tablets require protection from both light and excessive moisture. Therefore, the medicine must be kept in its original container, which should be kept tightly closed and stored away from high-humidity environments like bathrooms. As a mandatory safety precaution, the product must be stored out of the sight and reach of children.

Official Disposal Protocol

Unused or expired Monocard should be disposed of by following specific instructions provided in the drug labeling or by utilizing an official drug take-back program.

If a take-back program is unavailable and no specific flushing instruction is given, the medicine must be mixed with an undesirable substance (e.g., used coffee grounds), sealed in a container, and then discarded in the household trash. The empty prescription packaging must have all personal information scratched out before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Monocard found in:

A-Z Index: